Skip to main content
. 2021 Feb 17;87(2):801–805. doi: 10.1097/QAI.0000000000002642

FIGURE 1.

FIGURE 1.

Virologic outcomes after switch to DOR/3TC/TDF (FDA Snapshot approach). Nine participants in the ISG who completed the base study (with HIV-1 RNA <40 copies/mL) but did not enter extension-1 were excluded from the week 144 analysis. ISG, immediate switch group. DSG, delayed switch group; FDA, Food and Drug Administration.